Vaccitech to Present at Upcoming September Investors Conferences
08 September 2022 - 6:01AM
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical
company engaged in the discovery and development of novel
immunotherapeutics and vaccines, today announced that the Company’s
Chief Executive Officer, Bill Enright, and Chief Financial Officer,
Georgy Egorov, will be participating in the following investment
conferences in September.
Event: |
Morgan Stanley 20th
Annual Healthcare Conference 2022, New York
City |
Date: |
Monday, September 12 –
Wednesday, September 14 |
Presentation: |
Fireside Chat |
Time: |
1:40 – 2:10 p.m. EDT on
Monday, September 12 |
|
|
Event: |
H.C. Wainwright
24th Annual
Global Investment Conference, New York City |
Date: |
Monday, September 12 –
Wednesday, September 14 |
Presentation: |
Company Overview |
Time: |
10:30 a.m. EDT on Wednesday,
September 14 |
Webcast: |
Events section of the
Vaccitech website |
Alongside the events listed above, the Company will
participate in 1x1 investor meetings that can be booked with the
relevant bank representatives or directly with the
Company.
About Vaccitech plcVaccitech (“the
Company”) is a clinical-stage biopharmaceutical company engaged in
the discovery and development primarily of novel immunotherapies
for the treatment of chronic infectious diseases, cancer,
autoimmunity and diseases where the T cell arm of the immune system
is believed to play an important role. The company’s proprietary
platforms include modified simian adenoviral vectors (ChAdOx1 and
ChAdOx2), other viral vectors including the well-validated Modified
Vaccinia Ankara (MVA) and synthetic nano-particle technologies
(SNAPvax™ and Syntholytic™). The combination of different
technologies in a mix and match approach (heterologous prime-boost)
consistently generates significantly higher magnitudes of T cells
compared with other technologies and approaches. The company has a
broad pipeline of both clinical and preclinical stage therapeutic
programs to treat solid tumors, chronic viral infections, as well
as a few prophylactic viral vaccine programs. Vaccitech co-invented
a COVID-19 vaccine with the University of Oxford, now approved for
use in many territories and exclusively licensed worldwide to
AstraZeneca through Oxford University Innovation, or OUI. Vaccitech
is entitled to receive a share of all milestones and royalty income
received by OUI from AstraZeneca.
Vaccitech Media contacts:Katja
Stout, Scius Communications (EU)Direct: +44 (0)
7789435990Email: katja@sciuscommunications.com
Katie Larch / Robert Flamm, Ph.D., Burns McClellan,
Inc.
(U.S.)Email: klarch@burnsmc.com / rflamm@burnsmc.com
Georgy Egorov, CFO,
VaccitechEmail: IR@vaccitech.co.uk
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From May 2024 to Jun 2024
Vaccitech (NASDAQ:VACC)
Historical Stock Chart
From Jun 2023 to Jun 2024